Table 2 Cox regression models for overall survival, recurrence-free-survival, and colostomy-free survival for patients living with HIV treated with definitive chemoradiation
| Â | Overall survival (OS) | Recurrence-free Survival (RFS) | Colostomy-free Survival (CFS) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate Model | Adjusted Model | Univariate Model | Adjusted Model | Univariate Model | Adjusted Model | |||||||
HR (95%CI) | p-value | HR (95%CI) | p-value | HR (95%CI) | p-value | HR (95%CI) | p-value | HR (95%CI) | p-value | HR (95%CI) | p-value | |
Age at diagnosis | ||||||||||||
  < 40 | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |
 40–59 | 0.78 (0.37–1.64) | 0.51 | 0.69 (0.29–1.60) | 0.39 | 0.65 (0.29–1.47) | 0.30 | 0.66 (0.28–1.54) | 0.34 | 0.99 (0.29–3.41) | 0.98 | 0.94 (0.26–3.34) | 0.92 |
 60+ | 1.44 (0.66–3.17) | 0.36 | 1.65 (0.67–4.05) | 0.28 | 0.60 (0.24–1.51) | 0.28 | 0.53 (0.20–1.43) | 0.21 | 0.87 (0.22–3.48) | 0.85 | 0.79 (0.19–3.23) | 0.74 |
Race/Ethnicity | ||||||||||||
 Caucasian | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |
 African American | 1.25 (0.82–1.89) | 0.29 | 1.31 (0.83–2.06) | 0.25 | 1.32 (0.79–2.18) | 0.29 | 1.17 (0.67–2.04) | 0.57 | 0.98 (0.47–2.01) | 0.95 | 1.06 (0.50–2.27) | 0.87 |
 Hispanic | 0.68 (0.29–1.60) | 0.38 | 0.69 (0.27–1.81) | 0.45 | 0.71 (0.25–2.02) | 0.52 | 0.65 (0.22–1.94) | 0.44 | 0.99 (0.29–3.35) | 0.99 | 1.17 (0.33–4.12) | 0.81 |
Oher/Unknown | 1.64 (0.80–3.33) | 0.18 | 2.10 (0.93–4.74) | 0.07 | 0.98 (0.35–2.77) | 0.97 | 1.36 (0.46–4.06) | 0.58 | 1.39 (0.41–4.71) | 0.60 | 1.22 (0.35–4.24) | 0.75 |
HIV Medication | ||||||||||||
 No Protease Inhibitor | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |
 Protease Inhibitor | 1.04 (0.68–1.59) | 0.87 | 0.86 (0.53–1.38) | 0.53 | 1.53 (0.86–2.72) | 0.15 | 1.34 (0.74–2.43) | 0.33 | 1.07 (0.52–2.23) | 0.85 | 1.03 (0.49–2.15) | 0.94 |
Year HIV Diagnosed | ||||||||||||
  < 2000 | 1.00 | Ref |  |  | 1.00 | Ref |  |  | 1.00 | Ref |  |  |
 2000–2009 | 0.77 (0.48–1.22) | 0.26 |  |  | 0.82 (0.47–1.43) | 0.48 |  |  | 1.22 (0.61–2.45) | 0.58 |  |  |
 2010–2016 | 0.98 (0.42–2.27) | 0.96 |  |  | 0.63 (0.19–2.01) | 0.43 |  |  | – | – |  |  |
Smoker | ||||||||||||
 Never | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |  |  | 1.00 | Ref |  |  |
 Former | 1.76 (0.96–3.22) | 0.07 | 1.65 (0.82–3.29) | 0.16 | 2.01 (1.01–4.00) | 0.05 |  |  | 1.14 (0.47–2.77) | 0.77 |  |  |
 Current | 1.45 (0.88–2.40) | 0.15 | 1.51 (0.83–2.77) | 0.18 | 1.12 (0.62–2.04) | 0.71 |  |  | 0.60 (0.28–1.27) | 0.18 |  |  |
 Unknown | 2.54 (1.16–5.55) | 0.02 | 4.08 (1.71–9.73) | < 0.01 | 0.97 (0.28–3.35) | 0.97 |  |  | 0.84 (0.19–3.73) | 0.82 |  |  |
Stage | ||||||||||||
 I | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |  |  |
 II | 2.38 (1.17–4.82) | 0.02 | 3.16 (1.50–6.62) | < 0.01 | 1.75 (0.77–3.97) | 0.18 | 1.77 (0.75–4.16) | 0.19 | 2.06 (0.70–6.00) | 0.19 |  |  |
 IIIA | 2.94 (1.16–7.41) | 0.02 | 4.63 (1.67–12.82) | < 0.01 | 1.88 (0.60–5.93) | 0.28 | 2.03 (0.62–6.62) | 0.24 | 2.71 (0.68–10.86) | 0.16 |  |  |
 IIIB | 3.07 (1.44–6.53) | < 0.01 | 3.16 (1.42–7.06) | < 0.01 | 3.10 (1.32–7.31) | < 0.01 | 3.01 (1.20–7.55) | 0.02 | 1.98 (0.59–6.59) | 0.27 |  |  |
 IV | 3.83 (1.18–12.47) | 0.03 | 2.41 (0.69–8.42) | 0.17 | 5.73 (1.67–19.6) | < 0.01 | 6.14 (1.68–22.44) | < 0.01 | – | – |  |  |
 Unknown | 3.66 (0.79–16.99) | 0.10 | 0.94 (0.17–5.11) | 0.94 | – | – | – | – | – | – |  |  |
CD4 at Cancer Diagnosis | ||||||||||||
  ≤ 200 | 1.00 | Ref |  |  | 1.00 | Ref |  |  | 1.00 | Ref |  |  |
  > 200 | 0.90 (0.58–1.41) | 0.66 |  |  | 0.63 (0.38–1.06) | 0.08 |  |  | 1.09 (0.49–2.42) | 0.83 |  |  |
 Unknown | 1.00 (0.41–2.47) | 0.99 |  |  | 0.59 (0.17–2.01) | 0.40 |  |  | 1.78 (0.46–6.93) | 0.40 |  |  |
Nadir CD4 during Radiation | ||||||||||||
  ≤ 200 | 1.00 | Ref |  |  | 1.00 | Ref |  |  | 1.00 | Ref |  |  |
  > 200 | 0.74 (0.45–1.22) | 0.24 |  |  | 0.75 (0.42–1.33) | 0.32 |  |  | 0.88 (0.40–1.90) | 0.74 |  |  |
 Unknown | 2.54 (1.16–5.55) | 0.76 |  |  | 0.64 (0.35–1.15) | 0.13 |  |  | 0.73 (0.33–1.62) | 0.43 |  |  |
BMI | ||||||||||||
  < 25 | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |  |  |
 25–29.9 | 0.72 (0.47–1.11) | 0.14 | 0.49 (0.30–0.81) | < 0.01 | 0.84 (0.50–1.42) | 0.51 | 0.62 (0.34–1.11) | 0.11 | 1.09 (0.55–2.18) | 0.81 |  |  |
 ≥ 30 | 0.39 (0.17–0.91) | 0.03 | 0.61 (0.25–1.51) | 0.29 | 0.30 (0.09–0.95) | 0.04 | 0.32 (0.10–1.06) | 0.06 | 0.22 (0.03–1.61) | 0.14 |  |  |
 Unknown | 1.09 (0.51–2.32) | 0.82 | 0.76 (0.32–1.77) | 0.52 | 0.88 (0.31–2.52) | 0.82 | 0.71 (0.24–2.13) | 0.54 | 1.35 (0.39–4.72) | 0.63 |  |  |
Alcohol Use | ||||||||||||
 No | 1.00 | Ref |  |  | 1.00 | Ref |  |  | 1.00 | Ref |  |  |
 Yes | 0.93 (0.63–1.40) | 0.74 |  |  | 0.69 (0.41–1.16) | 0.16 |  |  | 0.85 (0.43–1.70) | 0.65 |  |  |
History of prior cancer | ||||||||||||
 No | 1.00 | Ref |  |  | 1.00 | Ref |  |  | 1.00 | Ref |  |  |
 Yes | 0.87 (0.51–1.48) | 0.60 |  |  | 0.71 (0.35–1.43) | 0.33 |  |  | 0.91 (0.38–2.18) | 0.83 |  |  |
Radiation Modality | ||||||||||||
 2D + 3D | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |  |  | 1.00 | Ref |  |  |
 IMRT | 0.65 (0.40–1.06) | 0.08 | 0.50 (0.29–0.86) | 0.01 | 0.70 (0.39–1.26) | 0.23 |  |  | 0.59 (0.25–1.39) | 0.22 |  |  |
 Unknown | 0.72 (0.46–1.13) | 0.15 | 0.60 (0.36–0.98) | 0.04 | 0.78 (0.45–1.37) | 0.39 |  |  | 0.99 (0.48–2.05) | 0.97 |  |  |
Completed Radiation Treatment | ||||||||||||
 No | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |  |  |
 Yes | 0.40 (0.23–0.69) | < 0.01 | 0.26 (0.14–0.50) | < 0.01 | 0.61 (0.30–1.24) | 0.17 | 0.44 (0.20–0.95) | 0.04 | 1.56 (0.37–6.51) | 0.54 |  |  |
Length of Radiation Treatment | ||||||||||||
  ≤ 50 days | 1.00 | Ref |  |  | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |
  > 50 days | 1.67 (1.13–2.47) | 0.01 |  |  | 1.48 (0.91–2.43) | 0.12 | 1.14 (0.66–1.97) | 0.63 | 1.55 (0.77–3.10) | 0.22 | 1.56 (0.77–3.17) | 0.22 |
 Unknown | 2.54 (1.16–5.55) | 0.15 |  |  | 2.87 (1.11–7.39) | 0.03 | 3.63 (1.32–9.99) | 0.01 | 5.34 (1.94–14.71) | < 0.01 | 5.48 (1.93–15.55) | < 0.01 |
Chemotherapy Regimen | ||||||||||||
 5FU + mitomycin C | 1.00 | Ref |  |  | 1.00 | Ref |  |  | 1.00 | Ref |  |  |
 5FU + cisplatin | 1.39 (0.81–2.39) | 0.23 |  |  | 0.84 (0.38–1.84) | 0.66 |  |  | 1.91 (0.82–4.46) | 0.13 |  |  |
 Other | 1.07 (0.63–1.85) | 0.80 |  |  | 0.92 (0.47–1.81) | 0.81 |  |  | 1.44 (0.62–3.37) | 0.40 |  |  |
Chemotherapy Dose Reduction | ||||||||||||
 No | 1.00 | Ref |  |  | 1.00 | Ref |  |  | 1.00 | Ref |  |  |
 Yes | 1.40 (0.94–2.08) | 0.10 |  |  | 1.46 (0.90–2.39) | 0.13 |  |  | 1.23 (0.62–2.45) | 0.56 |  |  |
Hospitalization during treatment | ||||||||||||
 No | 1.00 | Ref | 1.00 | Ref | 1.00 | Ref |  |  | 1.00 | Ref |  |  |
 Yes | 2.05 (1.40–3.00) | < 0.01 | 1.92 (1.24–2.96) | < 0.01 | 2.05 (1.28–3.30) | < 0.01 |  |  | 1.37 (0.71–2.64) | 0.35 |  |  |